Leukemogenic effect of chemotherapy in patients with breast carcinoma: Is it a real concern?

Cancer

Volumn 101, Issue 7, 2004, Pages 1479-1481

  Ibrahim, Nuhad K ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; PODOPHYLLOTOXIN;

BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; HUMAN; LEUKEMIA; LEUKEMOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; HUMANS; LEUKEMIA; NEOPLASMS, SECOND PRIMARY;

EID: 4844223385     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20525     Document Type: Review

References (18)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8-29.
2. Peto R, Boreham J, Clarke M, Davies C, Beral V. UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet. 2000;355:1822.
3. Visani F, Pagano L, Pulsoni A, et al. Chemotherapy of secondary leukemias. Leuk Lymphoma. 2000;37:543-549.
4. Fisher B, Rockette H, Fisher ER, Wickerham DL, Redmond C, Brown A. Leukemia in breast cancer patients following adjuvant chemotherapy or postoperative radiation: the NSABP experience. J Clin Oncol. 1985;2:1640-1658.
5. Curtis RE, Boice JD, Moloney WC, Ries LG, Flannery JT. Leukemia following chemotherapy for breast cancer. Cancer Res. 1990;50:2741-2746.
6. Le Deley MC, Leblanc T, Shamsaldin A, et al. Risk of secondary leukemia after solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case-control study by the Societe Francaise d'Oncologic Pediatrique. J Clin Oncol. 2003;21:1074-1081.
7. Daheron L, Veinstein A, Brizard F, et al. Human LLP gene is fused to MLL in a secondary acute leukemia. Genes Chromosomes Cancer. 2001;31:382-389.
8. Yagita M, Ieki Y, Onishi R, et al. Therapy-related leukemia and myelodysplasia following oral administration of etoposide for recurrent breast cancer. Int J Oncol. 1998;13:91-96.
9. Curtis RE, Boice JD, Stovall M, Flannery JT, Moloney WC. Leukemia risk following radiotherapy for breast cancer. J Clin Oncol. 1989;7:21-29.
10. Diamandidou E, Buzdar AU, Smith TL, Frye D, Witjaksono M, Hortobagyi GN. Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: the University of Texas M. D. Anderson Cancer Center experience. J Clin Oncol. 1996;14:2722-2730.
11. Curtis RE, Boice JD, Stovall M, et al. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med. 1992;326:1745-1751.
12. Kaplan G, Malmgren JA, Atwood M. Leukemia following breast carcinoma treatment. Cancer. 2004;101:1529-1536.
13. Knutsen T, Pack S, Petropavlovskaja M, et al. Cytogenetic, spectral karyotyping, fluorescence in situ hybridization, and comparative genomic hydridization characterization of two new secondary leukemia cell lines with 5q deletions, and MYC and MLL amplification. Genes Chromosomes Cancer. 2003;37:270-281.
14. Leone G, Voso MT, Sica S, Morosetti R, Pagano L. Therapy related leukemias: susceptibility, prevention and treatment. Leuk Lymphoma. 2001;41:255-276.
15. Silva ML, Land MG, Maradei S, et al. Translocation (11; 11)(p13-p15;q23) in a child with therapy-related acute myeloid leukemia following chemotherapy with DNA-topoisomerase II inhibitors for Langerhans cell histiocytosis. Cancer Genet Cytogenet. 2002;135:101-102.
16. Daheron L, Veinstein A, Brizard F, et al. Human LLP gene is fused to MLL in a secondary acute leukemia with a t(3; 11)(q28;q23). Genes Chromosomes Cancer. 2001;31:382-389.
17. Van Leeuwen FE, Travis LB. Second cancers. In: DeVita VT, Hellmann S, Rosenberg SA, editors. Cancer: principles and practice of oncology (6th edition). Philadelphia: Lippincott Williams & Wilkins, 2001:2939-2964.
18. Ravdin PM, Siminoff IA, Harvey JA. Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy. J Clin Oncol. 1998;16:515-521.